273 related articles for article (PubMed ID: 36499382)
1. Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance.
Wu J; Lin Z
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499382
[TBL] [Abstract][Full Text] [Related]
2. SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy.
Drilon A; Sharma MR; Johnson ML; Yap TA; Gadgeel S; Nepert D; Feng G; Reddy MB; Harney AS; Elsayed M; Cook AW; Wong CE; Hinklin RJ; Jiang Y; Brown EN; Neitzel NA; Laird ER; Wu WI; Singh A; Wei P; Ching KA; Gaudino JJ; Lee PA; Hartley DP; Rothenberg SM
Cancer Discov; 2023 Aug; 13(8):1789-1801. PubMed ID: 37269335
[TBL] [Abstract][Full Text] [Related]
3. Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update.
Roskoski R
Pharmacol Res; 2024 Feb; 200():107059. PubMed ID: 38216005
[TBL] [Abstract][Full Text] [Related]
4. Novel Approach to Accelerate Lung Cancer Research: Lung-MAP and the Potential of Public-Private Partnerships.
Herbst RS; Blanke CD; Sigal EV
Clin Cancer Res; 2024 Jan; 30(1):29-32. PubMed ID: 37903180
[TBL] [Abstract][Full Text] [Related]
5. Targeting MET in NSCLC: An Ever-Expanding Territory.
Han Y; Yu Y; Miao D; Zhou M; Zhao J; Shao Z; Jin R; Le X; Li W; Xia Y
JTO Clin Res Rep; 2024 Feb; 5(2):100630. PubMed ID: 38361739
[TBL] [Abstract][Full Text] [Related]
6. Editorial: Mechanisms of drug resistance to targeted therapy in malignancies.
Hamaji M
Front Oncol; 2024; 14():1363808. PubMed ID: 38313799
[No Abstract] [Full Text] [Related]
7. Lung cancer immunotherapy: progress, pitfalls, and promises.
Lahiri A; Maji A; Potdar PD; Singh N; Parikh P; Bisht B; Mukherjee A; Paul MK
Mol Cancer; 2023 Feb; 22(1):40. PubMed ID: 36810079
[TBL] [Abstract][Full Text] [Related]
8. Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer.
Wang Z; Xing Y; Li B; Li X; Liu B; Wang Y
Mol Biomed; 2022 Dec; 3(1):42. PubMed ID: 36508072
[TBL] [Abstract][Full Text] [Related]
9. EML4-ALK biology and drug resistance in non-small cell lung cancer: a new phase of discoveries.
Elshatlawy M; Sampson J; Clarke K; Bayliss R
Mol Oncol; 2023 Jun; 17(6):950-963. PubMed ID: 37149843
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.
Herbst RS; Wu YL; John T; Grohe C; Majem M; Wang J; Kato T; Goldman JW; Laktionov K; Kim SW; Yu CJ; Vu HV; Lu S; Lee KY; Mukhametshina G; Akewanlop C; de Marinis F; Bonanno L; Domine M; Shepherd FA; Urban D; Huang X; Bolanos A; Stachowiak M; Tsuboi M
J Clin Oncol; 2023 Apr; 41(10):1830-1840. PubMed ID: 36720083
[TBL] [Abstract][Full Text] [Related]
11. Long non-coding RNAs in non-small cell lung cancer: implications for EGFR-TKI resistance.
Liu D; Lu X; Huang W; Zhuang W
Front Genet; 2023; 14():1222059. PubMed ID: 37456663
[TBL] [Abstract][Full Text] [Related]
12. Advances in Genomic Data and Biomarkers: Revolutionizing NSCLC Diagnosis and Treatment.
Restrepo JC; Dueñas D; Corredor Z; Liscano Y
Cancers (Basel); 2023 Jul; 15(13):. PubMed ID: 37444584
[TBL] [Abstract][Full Text] [Related]
13. The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies.
Laface C; Maselli FM; Santoro AN; Iaia ML; Ambrogio F; Laterza M; Guarini C; De Santis P; Perrone M; Fedele P
Pharmaceutics; 2023 May; 15(6):. PubMed ID: 37376053
[TBL] [Abstract][Full Text] [Related]
14. Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story?
Spagnolo CC; Ciappina G; Giovannetti E; Squeri A; Granata B; Lazzari C; Pretelli G; Pasello G; Santarpia M
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373267
[TBL] [Abstract][Full Text] [Related]
15. [Research Progress in Immune Checkpoint Inhibitors Combination Therapy Applied to
Non-small Cell Lung Cancer after EGFR Mutation-targeted Therapy Resistance].
Li J; Yao X; Qiu L; Zhang R; Wang G
Zhongguo Fei Ai Za Zhi; 2023 May; 26(5):392-399. PubMed ID: 37316449
[TBL] [Abstract][Full Text] [Related]
16. Liquid Biopsy in Lung Cancer: Biomarkers for the Management of Recurrence and Metastasis.
Souza VGP; Forder A; Brockley LJ; Pewarchuk ME; Telkar N; de Araújo RP; Trejo J; Benard K; Seneda AL; Minutentag IW; Erkan M; Stewart GL; Hasimoto EN; Garnis C; Lam WL; Martinez VD; Reis PP
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240238
[TBL] [Abstract][Full Text] [Related]
17. Emerging evidence and treatment paradigm of non-small cell lung cancer.
Liu SM; Zheng MM; Pan Y; Liu SY; Li Y; Wu YL
J Hematol Oncol; 2023 Apr; 16(1):40. PubMed ID: 37069698
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study.
Garassino MC; Gadgeel S; Speranza G; Felip E; Esteban E; Dómine M; Hochmair MJ; Powell SF; Bischoff HG; Peled N; Grossi F; Jennens RR; Reck M; Hui R; Garon EB; Kurata T; Gray JE; Schwarzenberger P; Jensen E; Pietanza MC; Rodríguez-Abreu D
J Clin Oncol; 2023 Apr; 41(11):1992-1998. PubMed ID: 36809080
[No Abstract] [Full Text] [Related]
19. ALK-positive lung cancer: a moving target.
Schneider JL; Lin JJ; Shaw AT
Nat Cancer; 2023 Mar; 4(3):330-343. PubMed ID: 36797503
[TBL] [Abstract][Full Text] [Related]
20. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Hendriks LE; Kerr KM; Menis J; Mok TS; Nestle U; Passaro A; Peters S; Planchard D; Smit EF; Solomon BJ; Veronesi G; Reck M;
Ann Oncol; 2023 Apr; 34(4):358-376. PubMed ID: 36669645
[No Abstract] [Full Text] [Related]
[Next] [New Search]
